AMRI was awarded a five-year federal contract from the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH), for drug substance development and manufacturing services. The NCATS award will support the Division of Pre-Clinical Innovation’s (DPI) drug development programs by providing drug substance development and manufacturing services related to the synthesis and analysis of small molecules. 

The goal of the DPI is to advance collaborative research projects across preclinical phases of the translational science spectrum. For this contract, AMRI will support the DPI scientists to advance early stage NCATS drug discovery projects from candidate nomination to clinical trials, providing services related to process development, analytical development and GMP manufacture of small molecule drug candidates to support clinical trials. 

“Our mission is to provide our customers a complete suite of services across the drug discovery, development and manufacturing continuum for the advancement of much needed medicines to improve patient outcomes,” said Christopher Conway, senior vice president of Drug Discovery, Development and Analytical Services (DDS). “AMRI is confident that our track record of success in advancing programs from pre-clinical to commercial launch will support NIH’s mission to translate scientific knowledge into effective therapies.”